Try our beta test site
73 studies found for:    pasireotide
Show Display Options
Rank Status Study
1 Completed
Has Results
Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
Condition: Hyperglycemia
Intervention: Drug: pasireotide
2 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease;   Acromegaly;   Neuroendocrine Tumors;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors;   Dumping Syndrome;   Prostate Cancer;   Melanoma Negative for bRAF;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
3 Terminated Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Condition: Gonadotroph Adenomas
Intervention: Drug: pasireotide LAR
4 Not yet recruiting Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment
Condition: Enterostomy
Interventions: Drug: Pasireotide;   Drug: Placebo
5 Recruiting Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Condition: Acromegaly
Intervention: Drug: Pasireotide LAR
6 Completed Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Interventions: Drug: SOM230;   Drug: RAD001
7 Recruiting SOM230 Ectopic ACTH-producing Tumors
Condition: Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide
8 Active, not recruiting Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Pasireotide with or without cabergoline
9 Active, not recruiting Pasireotide LAR and Pegvisomant Study in Acromegaly
Condition: Acromegaly
Interventions: Drug: Pasireotide LAR 60 mg;   Drug: Pegvisomant
10 Completed Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
11 Completed Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
Conditions: Hepatic Cirrhosis;   Alcoholism
Intervention: Drug: Pasireotide
12 Terminated
Has Results
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Conditions: Pancreatic Neoplasm;   Pituitary Neoplasm;   Nelson Syndrome;   Ectopic ACTH Syndrome
Intervention: Drug: pasireotide LAR
13 Recruiting Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Conditions: Pituitary Tumor;   ACTH-producing Pituitary Tumour
Intervention: Drug: Pasireotide LAR
14 Recruiting Pasireotide in Prevention of GI Toxicity
Condition: Hematological Malignancies
Interventions: Drug: Pasireotide + Chemo;   Drug: Pasireotide + Total Body Irradiation
15 Completed Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: PASIREOTIDE;   Drug: PLACEBO
16 Completed An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
17 Completed Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
Condition: Cushing Disease
Intervention: Drug: Pasireotide 0.6 MG/ML
18 Completed Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Biological: SOM230
19 Active, not recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
20 Terminated Pasireotide Therapy in Patients With Nelson's Syndrome
Condition: Nelson Syndrome
Intervention: Drug: Pasireotide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.